Table 1 Key results of the clinical trials included in the present analysis
From: Treatment of hepatitis C virus genotype 4 in the DAA era
Clinical trial or field experience | n° of patients with G4-infection | Treatment | SVR rate in GT4 patients |
|---|---|---|---|
Ruane 2015 [8] | 34 | SOF + RBV | 68–93% |
Feld 2015 [9] | 116 | SOF/VEL | 100% |
Curry 2015 [10] | 8 | SOF/VEL | 100% |
Gane 2016 [11] | 17 | SOF/VEL + VOX | 58% |
Bourliere 2017 [12] | 41 (POLARIS-1 + POLARIS-4) | SOF/VEL + VOX | 97% |
Colombo 2017 [13] | 10 | SOF/LDV | 100% |
Kholi 2015 [14] | 21 | SOF/LDV | 95% |
Buti 2017 [15] | 40 | SMV/SOF | 100% |
El Raziky 2017 [16] | 63 | SMV/SOF | 92% |
Kwo 2017 [17] | 37 | EBR + GZR | 89% |
Waked [18] | 160 | OBV/PTV/R/RBV | 93–94% |
Hézode 2015 [19] | 135 | OBV/PTV/r ± RBV | 100% with RBV, 91% without RBV |
Forns [20] | 16 | GLI/PIB | 100% |
Kwo [42] | 22(SURVEYOR-I and SURVEYOR-II) | GLI/ PIB | 100% |
Asselah [21] | SURVEYOR-II Part 4, ENDURANCE-4 and ENDURANCE-2) | GLI/ PIB | 93% 8 week treatment 99% 12 week treatment |
Yakoot [22] | 120 (randomized 60 in 12 weeks regimen and 60 in response tailored regimen) | SOF + DAC | 96.7% in the fixed regimen 98.4% in the response tailored regimen |
El-Khayat [23] | 551 cirrotic patients (432 naïve, 119 treatment experienced) | SOF + DAC + RBV | 92%in naïve 87% in experienced |
Willemse [24] | 53 (naïve and IFN experienced) | SOF + SIM | 92% |
Degre [25] | 87, IFN experienced | SOF + SIM ± RBV | 87.4% |
Elsharkawy 2017 [26] | 8742 (F3) 5667 (F3) | SOF/peg/IFN-RBV SOF/RBV | 94% 79% |
Asselah 2017 [27] | 67 naïve, F0-F2 | SIM + PEG IFN | 97% |
Ioannou [28] | 135 (two arm: 104, 31) | SOF/LDV ± RBV and OBV/PTV/r ± RBV | 89.6% |
Crespo [29] | 152 (two arm:130 and 122) | SOF/LDV ± RBV and OBV/PTV/r ± RBV | 95.4 and 96.2% |
Welzel [30] | 53 | OBV/PTV/r ± RBV | 100% |
Perello [31] | 87 (73% cirrhosis, 35% treatment naïve) | OBV/PTV/r ± RBV | 100% |
Petta 2017 [32] | 17 | OBV/PTV/r ± RBV | 94% |
Wedemeyer 2017 [33] | 112, 19 cirrhosis | OBV/PTV/r ± RBV | 96,5% |
Komatsu [34] | 26 | EBR + GZR | 100% |
Maria 2017 [35] | 7 | SOF ± SIM or DAC or LDV ± RBV | 100% |
Hezode 2016 [36] | 215 | SOF + DAC | 91% |
Babatin 2017 [37] | 40 35% cirrhotic; treatment-experienced 52.5% | SOF + DAC + RBV | 100% |
Abad 2017 [38] | 35 | OBV/PTV/r | 100% |
Ponziani 2017 [46] | 8 | OBV/PTV/r | 100% |
Manns 2016 [43] | 37 | SOF/LDV + RBV | 81% |